March 28, 2023Healthcare
News
March 6, 2023Healthcare
Teijin Pharma Grants Global Exclusive License for Investigational Small Molecule Candidate in Kidney Disease[Teijin Pharma] (PDF: 115.5 KB)
February 20, 2023Healthcare
Teijin and Axcelead, Inc. to Establish Drug Discovery Research JV[Teijin] (PDF: 133.5 KB)
January 30, 2023Healthcare
Teijin Pharma to Launch Japan-market Sales of Abaloparatide Acetate for Osteoporosis [Teijin Pharma] (PDF: 232.8 KB)
October 3, 2022Healthcare
Teijin Launches Teijin Meguro Institute to Strengthen Functional Food Ingredients Business[Teijin] (PDF: 130.7 KB)
September 27, 2022Healthcare
Teijin, J-TEC, Mitsui Fudosan Co., Ltd. and National Cancer Center to Establish Regenerative Medicine Platform[Teijin,Japan Tissue Engineering] (PDF: 432.2 KB)
September 5, 2022Healthcare
Teijin Pharma Receives Additional Approval in Japan for Abaloparatide Acetate as Treatment for Osteoporosis[Teijin Pharma] (PDF: 153.2 KB)
June 13, 2022Healthcare
Teijin to Launch BARLEYmax™ Super Barley in Europe[Teijin] (PDF: 212.7 KB)
May 17, 2022Healthcare
Osaka Medical and Pharmaceutical University, Fukui Tateami Co., Ltd. and Teijin Achieve Primary Endpoint in Cardiovascular Patch Clinical Trial[Teijin] (PDF: 195.6 KB)
April 18, 2022Healthcare
Teijin and JCR Pharmaceuticals Co., Ltd. Cease JTR-161 Dental Pulp Stem Cell Research[Teijin] (PDF: 137.8 KB)
April 5, 2022Healthcare
Iktos and Teijin Pharma to Co-Develop New Technology for Small Molecule Drug Discovery[Teijin Pharma] (PDF: 183.8 KB)
March 9, 2022Healthcare
Teijin’s BARLEYmax™ Super Barley Adopted by Taiwan MOS Burger[Teijin] (PDF: 226.8 KB)
February 1, 2022Healthcare
Anti-Tau Antibody created by Teijin Pharma and developed by Merck & Co., Inc., Kenilworth NJ USA Enters Clinical Development[Teijin Pharma] (PDF: 112.5 KB)
October 29, 2021Healthcare
Teijin Nakashima Medical to Acquire Otsuka Group Company’s Spine and Trauma Business[Teijin,Teijin Nakashima Medical] (PDF: 160.6 KB)
June 23, 2021Healthcare
Teijin Receives Additional Approval in Japan for Merz’s Xeomin® Botulinum Toxin Type A[Teijin Pharma] (PDF: 184.2 KB)
June 1, 2021Healthcare
Industry-Academia Collaborated Microstructure Spine-Fusing Device Now Covered Under Japanese National Health Insurance[Teijin Nakashima Medical] (PDF: 179.4 KB)
April 23, 2021Healthcare
Teijin and Jolly Good Inc. to Jointly Develop VR-based Depression-treatment System[Teijin Pharma] (PDF: 178.6 KB)
April 1, 2021HealthcareIR
Notice Regarding Completion of Transfer of Japan Sales of Type 2 Diabetes Treatments[Teijin] (PDF: 82.4 KB)
March 23, 2021Healthcare
Teijin to Commence Manufacture and Sale in Japan of Abaloparatide Acetate as Treatment for Osteoporosis[Teijin Pharma] (PDF: 177.3 KB)
February 26, 2021HealthcareIR
Notice Regarding Execution of Asset Transfer Agreement for Transfer of Japan Sales, Intellectual Properties, and Manufacturing and Marketing Approval of Type 2 Diabetes Treatments (Nesina®, Liovel®, Inisync®, and Zafatek®)[Teijin] (PDF: 206.4 KB)
January 27, 2021Healthcare
Targeted Number of Subjects Registered for Cardiovascular Patch Clinical Trial[Teijin] (PDF: 151.5 KB)
December 18, 2020Healthcare
Teijin Pharma and TransThera Biosciences Form Strategic R&D Collaboration[Teijin Pharma] (PDF: 142.9 KB)
December 4, 2020Healthcare
Teijin Starts Exclusive Sales of Merz’s Xeomin® Botulinum Toxin Type A in Japan[Teijin Pharma] (PDF: 169.0 KB)
August 7, 2020Healthcare
Teijin and CoreTissue BioEngineering Agree on Alliance to Mass Produce Artificial Ligament[Teijin] (PDF: 188.9 KB)
June 29, 2020Healthcare
Teijin Receives Marketing Approval for Merz’s Xeomin® Botulinum Toxin Type A in Japan[Teijin Pharma] (PDF: 210.7 KB)
May 27, 2020Healthcare
Teijin Applies for Approval to Manufacture and Sell Abaloparatide Acetate as Osteoporosis Treatment in Japan[Teijin Pharma] (PDF: 176.0 KB)
April 6, 2020Healthcare
Teijin to invest in U.S. Venture-capital Fund[Teijin] (PDF: 103.5 KB)
February 27, 2020Healthcare
Teijin Launches Super Barley in Asia[Teijin]
January 15, 2020Healthcare
Teijin Home Healthcare Limited to Change its Name[Teijin Pharma, Teijin Home Healthcare]
January 9, 2020Healthcare
Teijin Signs Agency Contract with Chr. Hansen to Start Probiotic Ingredients Business[Teijin]
September 20, 2019Healthcare
Results of Phase II Clinical Trials of New Drug Under Development[Teijin Pharma]
June 26, 2019Healthcare
Clinical Trial of New Cardiovascular Patch Launched[Teijin] (PDF: 128.0 KB)
June 13, 2019Healthcare
Teijin Acquires Exclusive Sales Rights in Asia to BARLEYmax®[Teijin]
June 5, 2019Healthcare
Teijin Pharma Starts to Exclusive Sales of Transcranial Magnetic Stimulation Device in Japan[Teijin Pharma]
May 29, 2019Healthcare
Teijin Pharma Launches Revcovi®, Japan’s First Drug for ADA Deficiency[Teijin Pharma]
May 16, 2019Healthcare
NOMON Launches Nicotinamide Mononucleotide Supplement for Productive Aging [Teijin]
May 16, 2019Healthcare
Teijin Establishes Nutraceutical Product Firm for Productive Aging[Teijin]
May 14, 2019Healthcare
Teijin and AMED Sign R&D Consignment Agreement to Develop Drugs for Frail[Teijin]
March 26, 2019Healthcare
Revcovi, Japan’s First Drug for ADA Deficiency, Receives Marketing Approval [Teijin Pharma]
March 26, 2019Healthcare
Obtainment of Manufacturing and Sales Approval for Etanercept Biosimilar, Anti-rheumatoid Arthritis Agent[Teijin]
February 6, 2019Healthcare
Administration of “JTR-161” Dental Pulp Stem Cells Product Starts in Clinical Trial in Japan[Teijin] (PDF: 190.2 KB)
February 4, 2019HealthcareCorporate
Teijin Board Elects Ichiro Watanabe as New President of Teijin Pharma[Teijin] (PDF: 162.8 KB)
February 28, 2018Healthcare
Teijin to Acquire Medical Device Company to Develop Ventricular Assist Devices[Teijin] (PDF: 132.8 KB)
February 14, 2018Healthcare
SanBio and Teijin to Terminate Licensing Agreement regarding SB623 for Stroke Treatment[Teijin] (PDF: 174.1 KB)
January 9, 2018Healthcare